Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

por Poels, Kamrine E., Schoenfeld, Adam J., Makhnin, Alex, Tobi, Yosef, Wang, Yuli, Frisco-Cabanos, Heidie, Chakrabarti, Shaon, Shi, Manli, Napoli, Chelsi, McDonald, Thomas O., Tan, Weiwei, Hata, Aaron, Weinrich, Scott L., Yu, Helena A., Michor, Franziska
Publicado 2021

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

por Poels, Kamrine E., Schoenfeld, Adam J., Makhnin, Alex, Tobi, Yosef, Wang, Yuli, Frisco-Cabanos, Heidie, Chakrabarti, Shaon, Shi, Manli, Napoli, Chelsi, McDonald, Thomas O., Tan, Weiwei, Hata, Aaron, Weinrich, Scott L., Yu, Helena A., Michor, Franziska
Publicado 2022

Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia

por Zee, Barry M., Poels, Kamrine E., Yao, Cong-Hui, Kawabata, Kimihito C., Wu, Gongwei, Duy, Cihangir, Jacobus, William D., Senior, Elizabeth, Endress, Jennifer E., Jambhekar, Ashwini, Lovitch, Scott B., Ma, Jiexian, Dhall, Abhinav, Harris, Isaac S., Blanco, M. Andres, Sykes, David B., Licht, Jonathan D., Weinstock, David M., Melnick, Ari, Haigis, Marcia C., Michor, Franziska, Shi, Yang
Publicado 2021

Roadmap on plasticity and epigenetics in cancer

por Foo, Jasmine, Basanta, David, Rockne, Russell C, Strelez, Carly, Shah, Curran, Ghaffarian, Kimya, Mumenthaler, Shannon M, Mitchell, Kelly, Lathia, Justin D, Frankhouser, David, Branciamore, Sergio, Kuo, Ya-Huei, Marcucci, Guido, Vander Velde, Robert, Marusyk, Andriy, Huang, Sui, Hari, Kishore, Jolly, Mohit Kumar, Hatzikirou, Haralampos, Poels, Kamrine E, Spilker, Mary E, Shtylla, Blerta, Robertson-Tessi, Mark, Anderson, Alexander R A
Publicado 2022